CSPC Ouyi opens dosing in Phase 1 trial of injectable pain drug SYH9089
The China-based trial moved from not-yet-recruiting to recruiting, with a safety readout due by year end that will test whether the injectable holds up against a crowded field of postoperative-pain drugs.
Executive Summary
- A Phase 1 trial of an injectable pain therapy moved from not-yet-recruiting to actively enrolling patients undergoing abdominal surgery, with enrollment held at its original target.
- The study is designed to establish an adverse-event profile first, with pain-control measures tracked as secondary evidence, positioning the readout as safety-first rather than efficacy-first.
- The candidate enters a postoperative-pain field with dozens of active programs spanning opioids, NSAIDs, local anesthetics and newer sodium-channel blockers, none of which share its specific molecular target.
- The trial's primary completion date sits at the end of 2026, setting up a safety-focused disclosure that will determine whether the program advances to a larger comparative study.
The status change
CSPC Ouyi Pharmaceutical Co., Ltd. updated the registry status of NCT07519109 from Not yet recruiting to Recruiting, a change logged on ClinicalTrials.gov on July 15, 2026. The trial is a Phase 1 study of SYH9089 injection in adults undergoing elective abdominal surgery with an expected incision length of 5 to 9 centimeters, testing the drug against an active comparator of ropivacaine hydrochloride and a placebo of 0.9% sodium chloride. The study started dosing on March 30, 2026, and lists a primary completion date of December 31, 2026, with a later overall completion date of March 31, 2027. NCT07519109+1Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.NCT07519109Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.Jul 15, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial measures
The registered primary endpoint is the adverse-event profile through 14 days after administration. Ten secondary endpoints track analgesic performance, including the area under the curve of pain-intensity scores at rest and with activity through 120 hours, cumulative use of rescue analgesics, time to first morphine rescue, and both investigator and participant satisfaction scores. That structure makes this a safety-first study: the trial is built to characterize tolerability of the injectable before any claim about pain control is tested in a larger, comparative design. NCT07519109Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.NCT07519109
Enrollment and protocol stability
The trial's target enrollment held at 60 patients with no change from its original figure, a pattern the operational model reads as typical for a Phase 1 study just beginning to recruit. Eligibility criteria were amended once, narrowing the anticipated incision length from 8 to 10 centimeters to 5 to 9 centimeters and adding new exclusion criteria for advanced malignant tumors and other confounding surgical interventions. The registry counts zero changes to the primary completion date and zero endpoint amendments since the study was first posted. That combination, a single eligibility refinement paired with a stable completion date and unchanged enrollment target, reads as routine trial administration rather than a signal of distress. NCT07519109Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.NCT07519109
The competitive field
Postoperative pain is a heavily populated indication: search of the field turned up more than 140 small-molecule trials, spanning opioids such as oxycodone and tramadol, NSAIDs such as ibuprofen and meloxicam, local anesthetics such as bupivacaine and ropivacaine, and newer entrants such as Vertex Pharmaceuticals' suzetrigine and Haisco Pharmaceutical's HSK21542, none of which target the same mechanism as SYH9089. SYH9089's own molecular target is not characterized in available records, which limits any claim about how it fits mechanistically among these comparators; the trial instead sits among a crowded but mechanistically varied field where an injectable's differentiation would need to come from its tolerability and dosing profile rather than a novel target. CSPC Ouyi has completed six of seven prior trials and had one terminated, a track record that carries no specific bearing on this asset's own safety outcome.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.